Investors

Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:
Lead Compound MSP-1014 demonstrating superior preclinical characteristics in head-to-head comparison with psilocybin
4 patent-pending new drug families drawing on novel chemical structures;
Over 75 compounds synthesized with preclinical data demonstrating promising results; and
Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Press Releases & News

Mindset Pharma to Participate in Stifel GMP’s The Future of Healthcare Conference on December 8th

December 2, 2021

Mindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

November 29, 2021

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021

November 8, 2021

H.C. Wainwright 2nd Annual Psychedelics Conference

December 6, 2021

Info

Stifel GMP’s The Future of Healthcare Conference

December 8, 2021

Info

2021 Annual and Special Meeting

Analyst Coverage

Firm

Maxim Group LLC

H.C. Wainwright & Co.

Analyst

Jason McCarthy, Ph.D.

Patrick R. Trucchio, CFA

Mindset Pharma Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Mindset Pharma Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Mindset Pharma Inc. or its management. Mindset Pharma Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.